Intensive glycaemic control does not seem to reduce all cause mortality in patients with type 2 diabetes .
OBJECTIVE To assess the effect of targeting intensive glycaemic control versus conventional glycaemic control on  all cause mortality and cardiovascular mortality , non-fatal myocardial infa rct ion , microvascular complications , and severe hypoglycaemia in patients with type 2 diabetes .
Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus.
OBJECTIVE The Veterans Affairs Cooperative Study in Diabetes Mellitus Type 2 Feasibility Trial ( VA CSDM ) studied st and ard and intensive glycemic treatment groups , achieving and maintaining for 27 months a difference in HbA1c of 2.1 % ( 9.2 % vs. 7.1 % , respectively ) . A sub study planned in advance examined health status as assessed by a health status question naire obtained at baseline and 24 months . DESIGN AND METHODS A r and omized , prospect i ve trial was carried out at five VA Medical Centers from 1990 to 1993 . The sample involved 153 male veterans 40 - 69 years of age and with diabetes duration of 8+/-4 years , who were suboptimally controlled with st and ard glucose lowering treatment .  The participants were r and omized to  intensive and st and ard treatment groups . In addition to a variety of indicators of glycemic control and complications , health-related qualify of life data were assessed using a 20- question version of the Medical Outcome Study instrument . Scores were evaluated at baseline and 24 months for changes between the treatment groups . RESULTS The two groups were similar at baseline with respect to age , duration of diabetes , complications , comorbidities , and reported physical activity . The intensive treatment group had more frequent , m and atory self-glucose monitoring ( vs. occasional measurement in the st and ard ) and received two or more daily insulin injections  ( only one in the st and ard ) . This group had three times the number of clinic visits and 10-fold higher reported incidence of mild/moderate hypoglycemia . There were no significant changes in the health status over time in either the st and ard or intensive treatment groups , nor was there a difference between the two groups . CONCLUSIONS Intensive glucose control in advanced Type 2 diabetes mellitus ( DM ) has no effect on health status over 2 years . The successful lowering of glycemia does not improve health-related quality of life nor do the increased dem and s of an intensive therapy regimen worsen it
Intensive glycaemic control does not seem to reduce all cause mortality in patients with type 2 diabetes .
OBJECTIVE To assess the effect of targeting intensive glycaemic control versus conventional glycaemic control on  all cause mortality and cardiovascular mortality , non-fatal myocardial infa rct ion , microvascular complications , and severe hypoglycaemia in patients with type 2 diabetes .